Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03900026 · ClinicalTrials.gov registry record · Phase 4
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
A Phase 4 study of Atherosclerosis and Vein Occlusion, sponsored by Unity Health Toronto.
- Completed
- Registry status
- Phase 4
- Development phase
- 782
- Enrollment target
- 20
- Study locations
NCT03900026: Completed Phase 4 study of Atherosclerosis and Vein Occlusion, sponsored by Unity Health Toronto.
NCT03900026 is a Phase 4 study of Atherosclerosis and Vein Occlusion that has completed, run by Unity Health Toronto. The registered enrollment target is 782 participants, below the 1,054-participant average among 69 other Atherosclerosis trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03900026, a Phase 4 study of Atherosclerosis and Vein Occlusion, has completed, sponsored by Unity Health Toronto.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 782 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if evolocumab added to regular statin therapy improves vein graft patency after coronary artery bypass graft (CABG) surgery.
Primary Outcome
Saphenous vein graft disease rate (VGDR) is defined as the proportion of vein grafts with significant stenosis or total occlusion (≥50%) on 64-slice (or greater) cardiac CT angiography (CTA) or clinically indicated coronary angiography.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Evolocumab
Study Locations (20)
Other
- Royal Adelaide Hospital - Adelaide
- Flinders Medical Centre - Bedford Park
- Monash University - Melbourne
- Fiona Stanley Hospital - Murdoch
- Foothills Medical Centre - Calgary
- Medical Centre Hungarian Defence Forces - Budapest
Ontario
- Hamilton Health Sciences - Hamilton
- Kingston Health Sciences Centre - Kingston
- One Heart Care - Mississauga
- North York Diagnostic and Cardiology Centre - North York
- Sunnybrook Health Sciences Center - North York
- St. Michael's Hospital - Toronto
California
- San Francisco VA Medical Center - San Francisco
Florida
- Jacksonville Center for Clinical Research - Jacksonville
Maine
- Maine Medical Center - Portland
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Ohio
- University Hospital Cleveland Medical Center - Cleveland
Alberta
- University of Alberta - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 782 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 4 |
What the finished NCT03900026 record still lists
NCT03900026 is an interventional study that assigns participants to a tested intervention. The registered 782 participants enrollment target is mid-sized for trials with a published cap, below the 1,054-participant average among 69 other Atherosclerosis trials with a reported enrollment target (26% lower).
The record links to 3 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03900026 names 20 study sites across 10 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT03900026 about?
NCT03900026 is a clinical study titled "Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery". The purpose of this study is to determine if evolocumab added to regular statin therapy improves vein graft patency after coronary artery bypass graft (CABG) surgery.
What is the current status of trial NCT03900026?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 782 participants. The study started on 2019-05-30. Estimated completion is 2025-01-30.
What conditions does trial NCT03900026 study?
This clinical trial studies the following conditions: Atherosclerosis, Vein Occlusion, Coronary Artery Bypass Graft Surgery.
What interventions are being tested in trial NCT03900026?
The interventions under investigation include: Placebo (OTHER), Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03900026?
This trial is sponsored by Unity Health Toronto, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03900026 being conducted?
This trial has 20 study locations across California, Florida, Maine, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03900026's enrollment target sits among peer trials
782 18th of 69 higher than 52 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RECRUITING · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
-
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06575192 · 783 participants · Phase 3
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI